| Maternal immune activation and abnormal brain development across CNS disorders I Knuesel, L Chicha, M Britschgi, SA Schobel, M Bodmer, JA Hellings, ... Nature Reviews Neurology 10 (11), 643-660, 2014 | 846 | 2014 |
| Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity RHP Porter, G Jaeschke, W Spooren, TM Ballard, B Büttelmann, ... Journal of Pharmacology and Experimental Therapeutics 315 (2), 711-721, 2005 | 335 | 2005 |
| A combined marble burying–locomotor activity test in mice: A practical screening test with sensitivity to different classes of anxiolytics and antidepressants LB Nicolas, Y Kolb, EPM Prinssen European journal of pharmacology 547 (1-3), 106-115, 2006 | 264 | 2006 |
| RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors TM Ballard, F Knoflach, E Prinssen, E Borroni, JA Vivian, J Basile, ... Psychopharmacology 202, 207-223, 2009 | 210 | 2009 |
| Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review S Toovey, C Rayner, E Prinssen, T Chu, B Donner, B Thakrar, ... Drug safety 31, 1097-1114, 2008 | 209 | 2008 |
| Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications LC Chiou, YY Liao, PC Fan, PH Kuo, CH Wang, C Riemer, EP Prinssen Current drug targets 8 (1), 117-135, 2007 | 175 | 2007 |
| Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds G Bruni, AJ Rennekamp, A Velenich, M McCarroll, L Gendelev, E Fertsch, ... Nature chemical biology 12 (7), 559-566, 2016 | 143 | 2016 |
| The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison TM Ballard, ML Woolley, E Prinssen, J Huwyler, R Porter, W Spooren Psychopharmacology 179, 218-229, 2005 | 135 | 2005 |
| CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor L Lindemann, G Jaeschke, A Michalon, E Vieira, M Honer, W Spooren, ... Journal of Pharmacology and Experimental Therapeutics 339 (2), 474-486, 2011 | 127 | 2011 |
| Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants N Parrott, B Davies, G Hoffmann, A Koerner, T Lave, E Prinssen, ... Clinical pharmacokinetics 50, 613-623, 2011 | 121 | 2011 |
| 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy EPM Prinssen, FC Colpaert, W Koek European journal of pharmacology 453 (2-3), 217-221, 2002 | 114 | 2002 |
| Characterization of (R,S)‐5,7‐di‐tert‐butyl‐3‐hydroxy‐3‐trifluoromethyl‐3H‐benzofuran‐2‐one as a positive allosteric modulator of GABAB receptors P Malherbe, R Masciadri, RD Norcross, F Knoflach, C Kratzeisen, ... British journal of pharmacology 154 (4), 797-811, 2008 | 110 | 2008 |
| Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys MC Ko, JH Woods, WE Fantegrossi, CM Galuska, J Wichmann, ... Neuropsychopharmacology 34 (9), 2088-2096, 2009 | 99 | 2009 |
| Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression L Lindemann, RH Porter, SH Scharf, B Kuennecke, A Bruns, ... Journal of Pharmacology and Experimental Therapeutics 353 (1), 213-233, 2015 | 94 | 2015 |
| Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer’s disease E Borroni, B Bohrmann, F Grueninger, E Prinssen, S Nave, H Loetscher, ... Journal of Pharmacology and Experimental Therapeutics 362 (3), 413-423, 2017 | 89 | 2017 |
| Evidence for a role of the shell of the nucleus accumbens in oral behavior of freely moving rats EP Prinssen, W Balestra, FF Bemelmans, AR Cools Journal of Neuroscience 14 (3), 1555-1562, 1994 | 84 | 1994 |
| Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects KN Murray, ME Edye, M Manca, AC Vernon, JM Oladipo, V Fasolino, ... Brain, behavior, and immunity 75, 48-59, 2019 | 83 | 2019 |
| Interactions between neuroleptics and 5-HT1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects EPM Prinssen, MS Kleven, W Koek Psychopharmacology 144, 20-29, 1999 | 80 | 1999 |
| Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics L Bardin, A Auclair, MS Kleven, EPM Prinssen, W Koek, ... Behavioural Pharmacology 18 (2), 103-118, 2007 | 75 | 2007 |
| Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets A Bespalov, T Steckler, B Altevogt, E Koustova, P Skolnick, D Deaver, ... Nature Reviews Drug Discovery 15 (7), 516-516, 2016 | 73 | 2016 |
